|
|
|
|
|
|
|
|
|
|
|
19.02.26 - 22:06
|
Guardant Health Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook (Business Wire)
|
|
|
Fourth quarter 2025 revenue growth of 39% broadly driven by strong performance across Oncology and Screening
Expects full year 2026 total revenue to grow in the range of 27% to 30% year-over-yearPALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter and full year ended December 31, 2025.
Fourth Quarter 2025 Financial Highlights
For the three-month period ended December 31, 2025, as compared to the same period of 2024:
Reported total revenue of $281.3 million, an increase of 39%, driven by:
Oncology revenue of $189.9 million, an increase of 30%, and approximately 79,000 oncology tests, an increase of 38%
Biopharma & Data revenue of $54.0 million, an increase of 9%
Screening revenue of $35.1 million, and approximately 38,000 Shield screening tests, compared to 6,400 tests in the prior year period
Generated non-GAAP gross margin of 66%, compared to 63% for the fourth quarter of 2024
Full Year 2025 Financia...
|
|
|
|
|
|
|
29.01.26 - 22:09
|
Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026 (Business Wire)
|
|
|
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 2025 after market close on Thursday, February 19, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com. The webcast will be archived and available for replay after the event.
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of ...
|
|
|
|
|
|
|
11.01.26 - 23:03
|
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results (Business Wire)
|
|
|
Fourth quarter revenue growth of 39% driven by strong Oncology and Screening volumePALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced preliminary, unaudited results for the quarter and full year ended December 31, 2025.
Fourth quarter 2025 preliminary unaudited financial results
For the three-month period ended December 31, 2025, as compared to the same period of 2024:
Total revenue of approximately $280 million, an increase of 39%
Reported approximately 79,000 oncology tests, an increase of 38%
Reported approximately 38,000 Shield screening tests, compared to 6,400 tests in the prior year period
Full year 2025 preliminary unaudited financial results
For the twelve-month period ended December 31, 2025, as compared to the same period of 2024:
Total revenue of approximately $981 million, an increase of 33%
Reported approximately 276,000 oncology tests, an increase of 34%
Reported approximately 87,000 Shield screening tests
“2025 wa...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
